Revenue segments as reported by the company.

U.S. Pharmaceutical

Prescription Technology Solutions

Medical-Surgical Solutions

International

Corporate

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, distribution, general, and administrative expenses

Claims and litigation charges, net

Restructuring, impairment, and related charges, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

McKesson

McKesson Corp. engages in the provision of supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology. It operates through the following segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products, provides practice management, technology, clinical support, and business solutions to community-based oncology, and other specialty practices, and sells financial, operational, and clinical solutions to pharmacies and provides consulting, outsourcing, technological, and other services. The International segment provides distribution and services to wholesale, institutional, and retail customers in European countries and Canada. The Medical-Surgical Solutions segment offers medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The RxTS segment brings together CoverMyMeds, RelayHealth, RxCrossroads, and McKesson Prescription Automation, including Multi-Client Central Fill as a Service, to serve biopharma and life sciences partners and patients. The company was founded by John McKesson and Charles Olcott in 1833 and is headquartered in Irving, TX.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

McKesson reports robust fiscal 2023 performance and focuses on sustainability

McKesson's Q4 fiscal 2023 earnings call highlighted strong financial performance, strategic priorities, and a focus on sustainability and employee recognition. The company faces challenges related to operational efficiencies and managing potential impacts from industry dynamics. However, it remains optimistic about opportunities for long-term growth and partnerships in the oncology space.

McKesson reports strong Q1 performance and anticipates sustained growth

McKesson's Q1 fiscal 2024 earnings call showcased strong financial performance, with a focus on prescription volume growth and expansion in the U.S. Oncology Network. The company faces potential fluctuations and timing challenges in its RxTS business but expects to benefit from volume-related factors and continual development. Overall, McKesson is well-positioned for sustainable growth and value creation.

McKesson excels in Q3, eyes oncology growth and sustainability

McKesson's Q3 performance was strong, with raised guidance and progress in strategic priorities.
The company's strengths lie in its focus on oncology, sustainability initiatives, and operational performance.
Challenges include macroeconomic factors, biosimilar management, and margin improvement strategies.
Opportunities in oncology growth, biosimilars, and strategic partnerships pave the way for future success.

McKesson reports robust earnings, poised for sustainable growth in healthcare

McKesson's Q4 2023 earnings call highlighted strong financial performance, strategic advancements, and a commitment to driving sustainable growth in key healthcare segments.
The company's focus on efficiency, sustainability, and employee engagement underpins its competitive strengths and resilience in a dynamic healthcare landscape.
While challenges such as industry fluctuations and regulatory dynamics exist, McKesson's strategic positioning, diverse business lines, and growth opportunities position it for continued success.
By leveraging opportunities in service expansion, biosimilars, and market trends, McKesson aims to enhance patient outcomes, drive revenue growth, and maintain its leadership in the healthcare services sector.

McKesson exceeds Q1 expectations, focuses on supply chain efficiency

McKesson delivered strong first-quarter results, exceeding revenue and earnings expectations.
The company's focus on enhancing supply chain efficiency and expanding relationships with manufacturers is driving growth.
Challenges include non-linear investments and the impact of 340B on pharmaceutical distribution business.
Opportunities lie in benefiting from volume-related factors, supporting product life cycles, and expanding oncology solutions.

McKesson excels in Q2, anticipates growth amid strategic investments

McKesson's Q2 performance reflects strong revenue growth and operational excellence across key segments.
The company's focus on employee well-being, technology solutions, and strategic investments positions it for continued success.
While facing competitive challenges in generics procurement, McKesson maintains stability and customer-centric supply.
Anticipated growth opportunities in fiscal 2024 and beyond underscore McKesson's commitment to innovation and operational efficiency.

McKesson reports robust Q3 earnings, eyes growth through strategic investments

McKesson's Q3 performance reflects strong revenue and earnings growth, supported by strategic initiatives and investments in key segments. While facing challenges like patient visit volumes and margin pressures, the company remains focused on driving sustainable growth and value delivery. Opportunities for growth through technology investments and segment expansions position McKesson for future success.

McKesson reports robust Q4 results, eyes growth in oncology services

McKesson's strong performance in Q4 '24 underscores its leadership in oncology and biopharma services, supported by strategic investments in AI and a new partnership with Optum. While facing challenges in pricing dynamics and 3PL business growth, the company is well-positioned to capitalize on opportunities in inorganic growth, AI utilization, and health equity initiatives.

McKesson reports solid Q1 growth, focuses on pharma innovation

McKesson's Q1 2025 showed solid revenue growth and increased earnings per share, driven by strong performance in pharmaceutical segments.
While facing challenges in the Medical-Surgical segment, the company aims to leverage strengths in distribution and technology investments for future growth.
Opportunities lie in capitalizing on pharmaceutical segment performance and driving innovation through technology investments.
Overall, McKesson's outlook for fiscal 2025 remains positive with projected revenue and profit growth.

McKesson posts record revenue, focuses on oncology for sustained growth

McKesson's strong financial performance and raised guidance reflect its resilience and strategic focus on growth.
While facing regulatory and integration challenges, the company's commitment to innovation and employee well-being positions it well for the future.
Opportunities lie in expanding market presence through acquisitions, influencing policy reforms, and optimizing operational efficiencies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

McKesson Corp. engages in providing healthcare services. It operates through the following segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs. The RxTS segment offers prescription price transparency, benefit insight, dispensing support services, third-party logistics, and wholesale distribution. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The International segment refers to the distribution and services to wholesale, institutional, and retail customers in Europe and Canada. The company was founded by John McKesson and Charles Olcott in 1833 and is headquartered in Irving, TX.

McKesson (MCK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for McKesson (MCK)

BancFirst

Dycom Industries

H&R Block

MGP Ingredients

Steel Dynamics

World Wrestling Entertainment

Everyone defines “boring stocks” differently, and everyone has their own ideas about criteria for the best boring stocks.  For example, I consider Mexican cement producer Cemex to be an incredibly dull stock.

The 7 Best Boring Stocks to Buy for Red-Hot Returns

Johnson & Johnson

Procter & Gamble

With fears of a recession rising, two of the three are already outperforming the S&P 500.

3 Warren Buffett Stocks That Should Beat the Market During a Recession

IRVING, Texas--(BUSINESS WIRE)--McKesson has opened a new state-of-the-art pharmaceutical distribution center in Jeffersonville, Ohio, located between Cincinnati and Columbus.

McKesson Opens Its Most Technologically Advanced Healthcare Distribution Center in Jeffersonville, Ohio

Amazon

Buffett doesn't flee bear markets. And neither should we.

2 Buffett Stocks to Buy More Of In October

Elevance Health Inc

Humana

All three stocks are up double-digit percentages in 2022, leaving the S&P 500's performance in the dust. With the stocks carrying favorable near-term earnings outlooks, the run could easily continue.

3 Top-Ranked Medical Stocks Lapping the S&P 500

McKesson's (MCK) fiscal second-quarter results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.

McKesson (MCK) to Report Q2 Earnings: Is a Beat in the Cards?

McKesson delivered share price gains and passive income so far this year.

Warren Buffett's Buying This Passive Income Stock: Should You?

Berkshire Hathaway increased its stake in this healthcare stock by 9.5% in the second quarter.

Is This Buffett-Backed Blue Chip Stock a Buy?

Boise Cascade

Iron Mountain

National Fuel Gas

RCI Hospitality

Boise Cascade (BCC), RCI Hospitality (RICK), Iron Mountain (IRM), McKesson (MCK) and National Fuel Gas (NFG) seem compelling picks for Q4 amid volatility.

5 Solid Dividend Growth Stocks for Q4

Occidental Petroleum

Many people turn to the Oracle of Omaha when looking for stocks to add. After all, it's easy to understand why after seeing his track record.

Should Investors Consider These 3 Warren Buffett Purchases?

Archer-Daniels-Midland Company

Consolidated Water

Lamb Weston Hlds

Here we mention four defensive stocks, namely Lamb Weston (LW), Consolidated Water (CWCO), Archer Daniels Midland (ADM) and McKesson (MCK) with strong prospects to beat the market volatility.

Grab These Top 4 Defensive Stocks to Beat the Market Doldrums

IRVING, Texas--(BUSINESS WIRE)--McKesson experts will play a major role in the AVBCC Summit, speaking on the changing healthcare landscape and transformation to value-based care.

McKesson Thought Leaders Are Key Presenters at 2022 Association for Value-Based Cancer Care Summit

Apple

American Express

Chevron

DaVita

Coca-Cola

Kroger

Warren Buffet's philosophy relies on identifying stocks to buy and hold. He believes that the best names to buy and hold are those of undervalued companies that have high chances of being successful over the long term.

7 Warren Buffett Stocks to Buy and Hold for the Next Decade

Carlisle Companies

Dollar Tree

All three companies have easily surpassed the S&P 500 average this year.

3 Stocks to Add to Your Portfolio in the Market Downturn

Biogen

Coterra Energy

McDonald's

Walmart

Exxon Mobil

Not all stocks are impacted equally by the economy slowing down. We look at stocks that have been winners during a down stock market thus far in 2022 while most of the rest of the market has fallen.

Recession Stocks: Finding Winners In A Down Stock Market

Aptiv Holdings Ltd

Baxter

Coca-Cola European Partners plc

Cigna

DXC Technology

Fiserv

Global Payments

Tenet Healthcare

US Foods Holding

Larry Robbins is the founder and CEO of Glenview Capital Management, which is a New York-based hedge fund.

These Are The Top 10 Holdings Of Larry Robbins

Hershey

Here we mention four defensive stocks, namely Lamb Weston (LW), Consolidated Water, McKesson and Hershey with strong prospects to stay afloat in the bear market.

4 Defensive Bets to Pacify Pessimists to Ride Market Storms

Molina Healthcare

Healthcare stocks generally carry a defensive nature, helping to shield investors from the market's volatility. Demand for the services these companies provide won't be going anywhere anytime soon.

3 Top-Ranked Healthcare Stocks Thriving in 2022

UnitedHealth Group

These healthcare giants benefit from industry trends.

2 Stocks Beating the Bear Market

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) today announced that it has signed an agreement in principle to extend its partnership with CVS Health to distribute pharmaceuticals to mail order and specialty pharmacies, retail pharmacies and distribution centers through June 2027. “We are pleased to continue our long-standing relationship with CVS Health and value the shared commitment of improving health outcomes for all patients,” said Brian Tyler, chief executive officer, M

McKesson Corporation Extends Pharmaceutical Distribution Agreement With CVS Health

Carlsberg AS

Hyatt Hotels

As brokers have a deeper understanding of stocks, one must follow rating upgrades before investing. We select Hyatt Hotels (H), McKesson (MCK) and Carlsberg (CABGY) as these have seen rating upgrades recently.

3 Stocks With Upgraded Broker Ratings for Impressive Returns

News for McKesson Stock (MCK)